Literature DB >> 24309014

Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.

Jered V McGivern1, Allison D Ebert2.   

Abstract

In order for the pharmaceutical industry to maintain a constant flow of novel drugs and therapeutics into the clinic, compounds must be thoroughly validated for safety and efficacy in multiple biological and biochemical systems. Pluripotent stem cells, because of their ability to develop into any cell type in the body and recapitulate human disease, may be an important cellular system to add to the drug development repertoire. This review will discuss some of the benefits of using pluripotent stem cells for drug discovery and safety studies as well as some of the recent applications of stem cells in drug screening studies. We will also address some of the hurdles that need to be overcome in order to make stem cell-based approaches an efficient and effective tool in the quest to produce clinically successful drug compounds.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiotoxicity; Disease modeling; Embryonic stem cells; Hepatotoxicity; High content screening; High throughput screening; Induced pluripotent stem cells

Mesh:

Year:  2013        PMID: 24309014     DOI: 10.1016/j.addr.2013.11.012

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  7 in total

1.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.

Authors:  Liang Guo; Sandy Eldridge; Mike Furniss; Jodie Mussio; Myrtle Davis
Journal:  Curr Protoc Chem Biol       Date:  2015-09-01

Review 2.  Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases.

Authors:  Kelly M Haston; Steven Finkbeiner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-28       Impact factor: 13.820

Review 3.  Technology advancement for integrative stem cell analyses.

Authors:  Yoon Jeong; Jonghoon Choi; Kwan Hyi Lee
Journal:  Tissue Eng Part B Rev       Date:  2014-07-03       Impact factor: 6.389

Review 4.  Stem Cells in Neurotoxicology/Developmental Neurotoxicology: Current Scenario and Future Prospects.

Authors:  S Singh; A Srivastava; V Kumar; A Pandey; D Kumar; C S Rajpurohit; V K Khanna; S Yadav; A B Pant
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

5.  Establishment of a translational endothelial cell model using directed differentiation of induced pluripotent stem cells from Cynomolgus monkey.

Authors:  Eva C Thoma; Tobias Heckel; David Keller; Nicolas Giroud; Brian Leonard; Klaus Christensen; Adrian Roth; Cristina Bertinetti-Lapatki; Martin Graf; Christoph Patsch
Journal:  Sci Rep       Date:  2016-10-25       Impact factor: 4.379

6.  Opportunities to Apply the 3Rs in Safety Assessment Programs.

Authors:  Fiona Sewell; Joanna Edwards; Helen Prior; Sally Robinson
Journal:  ILAR J       Date:  2016-12

7.  Tox_(R)CNN: Deep learning-based nuclei profiling tool for drug toxicity screening.

Authors:  Daniel Jimenez-Carretero; Vahid Abrishami; Laura Fernández-de-Manuel; Irene Palacios; Antonio Quílez-Álvarez; Alberto Díez-Sánchez; Miguel A Del Pozo; María C Montoya
Journal:  PLoS Comput Biol       Date:  2018-11-30       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.